On December 22, 2024, N2OFF entered into a Loan Agreement with MitoCareX Bio Ltd. and L.I.A. Pure Capital Ltd. N2OFF agreed to loan $250,000 to MitoCareX for six months, with interest accruing at the USD exchange rate fluctuation plus 3%. Pure Capital guaranteed the loan repayment. If MitoCareX becomes a subsidiary of N2OFF, the outstanding loan amount will be deducted from future allocations to MitoCareX within the first year.On December 23, 2024, N2OFF's board issued 650,000 shares of common stock under its 2022 Share Incentive Plan to directors for board service. This followed the non-binding advisory approval by stockholders at the annual meeting on November 13, 2024.

On December 22, 2024, N2OFF entered into a Loan Agreement with MitoCareX Bio Ltd. and L.I.A. Pure Capital Ltd. N2OFF agreed to loan $250,000 to MitoCareX for six months, with interest accruing at the USD exchange rate fluctuation plus 3%. Pure Capital guaranteed the loan repayment. If MitoCareX becomes a subsidiary of N2OFF, the outstanding loan amount will be deducted from future allocations to MitoCareX within the first year.On December 23, 2024, N2OFF's board issued 650,000 shares of common stock under its 2022 Share Incentive Plan to directors for board service. This followed the non-binding advisory approval by stockholders at the annual meeting on November 13, 2024.